Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (641-650 of 850) with videos related to

Pageof 85
Sort By:
Urologic Oncology|July 11, 2022
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy coreBenedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Oncology Reports|July 3, 2015
Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletionKatharina Grupp, Laura Roettger, Martina Kluth, et al.
BJU International|April 13, 2007
Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancerAndrea Gallina, Pierre I Karakiewicz, Felix K-H Chun, et al.
Seminars in Oncology|May 24, 2022
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumabRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
European Urology|July 4, 2012
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomyVincenzo Ficarra, Giacomo Novara, Thomas E Ahlering, et al.
Urologic Oncology|February 11, 2015
Natural history of surgically treated high-risk prostate cancerAlberto Briganti, Robert Jeffrey Karnes, Giorgio Gandaglia, et al.
The Prostate|April 11, 2022
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patientsRocco S Flammia, Benedikt Hoeh, Gabriele Sorce, et al.
European Urology|December 14, 2011
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancerAlberto Briganti, Steven Joniau, Paolo Gontero, et al.
BJU International|September 24, 2013
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason scoreJens Hansen, Marco Bianchi, Maxine Sun, et al.
International Urology and Nephrology|July 15, 2022
Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patientsRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
Pageof 85

Showing results (641-650 of 850) with videos related to

Sort By:
Pageof 85
Urologic Oncology|July 11, 2022
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy coreBenedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, et al.
Oncology Reports|July 3, 2015
Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletionKatharina Grupp, Laura Roettger, Martina Kluth, et al.
BJU International|April 13, 2007
Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancerAndrea Gallina, Pierre I Karakiewicz, Felix K-H Chun, et al.
Seminars in Oncology|May 24, 2022
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumabRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
European Urology|July 4, 2012
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomyVincenzo Ficarra, Giacomo Novara, Thomas E Ahlering, et al.
Urologic Oncology|February 11, 2015
Natural history of surgically treated high-risk prostate cancerAlberto Briganti, Robert Jeffrey Karnes, Giorgio Gandaglia, et al.
The Prostate|April 11, 2022
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patientsRocco S Flammia, Benedikt Hoeh, Gabriele Sorce, et al.
European Urology|December 14, 2011
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancerAlberto Briganti, Steven Joniau, Paolo Gontero, et al.
BJU International|September 24, 2013
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason scoreJens Hansen, Marco Bianchi, Maxine Sun, et al.
International Urology and Nephrology|July 15, 2022
Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patientsRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
Pageof 85